Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice
- 1 September 1989
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 14 (3) , 782-789
- https://doi.org/10.1016/0735-1097(89)90126-5
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure-overload left ventricular failure.Journal of Clinical Investigation, 1988
- Toward an understanding of the molecular basis of cardiomyopathiesJournal of the American College of Cardiology, 1987
- Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamsterJournal of the American College of Cardiology, 1987
- Loss of high affinity cardiac beta adrenergic receptors in dogs with heart failure.Journal of Clinical Investigation, 1985
- The interaction of verapamil and norverapamil with beta-adrenergic receptors.Circulation, 1985
- Adenylate cyclase activity during development and reversal of cardiac hypertrophyJournal of Molecular and Cellular Cardiology, 1985
- Preservation of high-energy phosphates by verapamil in reperfused myocardium.Circulation, 1984
- Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis.Circulation, 1982
- Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human HeartsNew England Journal of Medicine, 1982
- Electrophysiological study of Syrian hamster hereditary cardiomyopathyCardiovascular Research, 1978